Our Promise


FIRST to IMAGINE, FIRST to INVENT
FIRST to IMAGINE, FIRST to INVENT reflects the Sorin Group's Cardiac Rhythm Management Business Unit principles. It is based on the values and philosophies that together form our contribution to patients, their families and the medical community. 

Our graphic...
Symbolic of the IMAGINATION that physicians and engineers bring to patients through our INVENTED solutions; a brilliant blue sky encompassed by the distinctive shape of our device. FIRST to IMAGINE, FIRST to INVENT embodies creativity through applied engineering excellence; it is about translating imagination into clinically meaningful technology.
 

Clinically Meaningful Technology

We were pioneers in researching the effects of unnecessary ventricular pacing, which we understood contributed to a deterioration of the heart's condition. In 20031 we INVENTED and introduced AAISafeR™ in our Symphony pacemakers, the FIRST pacing mode designed to prevent unnecessary ventricular pacing. After years of clinical development, it has been shown that AAISafeR™, now SafeR™, ensures 99.9% intrinsic conduction2, preventing complications associated with over stimulation of the right ventricle. After confirmation through large clinical trials3, our initial idea of preventing unnecessary ventricular pacing has now been adopted in the American and European guidelines for cardiac pacing.

Innovative Leadership in the Hemodynamic Management of Heart Failure

We were the FIRST company to implant a bi-ventricular pacing system in 1994. A few years later, we initiated the MUSTIC trial: the first randomized clinical trial to demonstrate benefits of Cardiac Resynchronization Therapy (CRT) over optimal medical therapy for heart failure. CRT is now recognized as a Class 1a therapy in all major guidelines for the treatment of specific groups of heart failure patients.

In 1998, we IMAGINED a cardiac resynchronization therapy device which would adapt to the patient's ever-changing cardiac status automatically during the patient's normal life. In 2005, we started the CLEAR clinical study4. This was the FIRST study to compare the typical CRT optimization procedure using echocardiographic assessment with automatic CRT optimization using signals from an implanted sensor. The SonR sensor, INVENTED by Sorin Group, measures heart contractility and has multiple applications for the hemodynamic management of heart failure. In 2008, the world’s FIRST implant of PARADYM™ SonR™ 8770 CRT-D was performed, allowing for the continuous hemodynamic adjustment of CRT 5,6.

The Best Change Maker

WCAIn 2009, Sorin Group and Orange Business Services were awarded the “Best Change- Maker award” for our remote health monitoring and telemedicine solution. Delivered by the World Communication Awards (WCA), this is the telecommunication industry’s most prestigious prize for monumental business achievements. The WCA recognized our effort in developing a remote monitoring solution for cardiac patients by combining machine-to-machine and e-health technologies to improve patients’ quality of life. It is the FIRST time that any medical device company has ever been awarded such a prize.

Be the FIRST to Experience Innovation

We pursue the long-term vision of setting the pace of innovation and continually developing new ideas. Working with Sorin Group means being FIRST to experience innovation and technological excellence. With over 25% of our staff working in research and development, Sorin Group has a tradition of breakthroughs.

We challenge and will continue to challenge the status quo, daring to IMAGINE and explore new patient therapies and techniques in close partnership with expert cardiologists, electrophysiologists, heart failure specialists as well as leading university hospitals and academic institutions. Translating our imagination into clinically meaningful technology, we concentrate on what we do best: Cardiac Rhythm Management systems imagined, designed and built to save and improve lives.

 


1. AAIsafeR in Symphony©DR 2550 pacemakers. “99.9% intrinsic AV conduction in 28/35 (80%) of patients of non-selected DDD patients” Anselme, F., et al. First clinical results of AAIsafeR2, a new mode to prevent ventricular pacing. Heart Rhythm 2005; 2, supp 5; p4-99 (abs).
2. CE mark granted in 2003, FDA approval in 2005.
3. Ovatio DR 6550, Ovatio VR 6250, CE mark granted in 2005, FDA approval in 2006, September 2008 data.
4. April 2009 data.
5. 2009 Planned launch. Not available for distribution.
6. “Continuous monitoring of an endocardial index of myocardial contractility during head-up tilt test”. Deharo et al – Am Heart J 2000; 139:1022-30; REF 2: “Automatic optimization of resting and exercise AV intervals using a PEA sensor” Leung at al – PACE 2000;23:1672-1766